InvestorsHub Logo
Followers 102
Posts 17192
Boards Moderated 2
Alias Born 04/06/2015

Re: cooper2021 post# 337989

Friday, 10/15/2021 1:49:56 PM

Friday, October 15, 2021 1:49:56 PM

Post# of 344002
$FORW CEO has delivered as always we will be seeing a FDA submission this year !!!!

https://www.ligandglobal.com/


Forwardly’s Ligand Innovation Global Makes Significant Strides Towards FDA Submission


Mississauga, ON and Henderson, NV, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Dr. Dayo Olakulehin, CEO of Ligand Innovation Global, Inc., (“Ligand”) a partially owned company and partner of Forwardly, Inc. (OTCMKT: FORW), announced today that the Ligand has achieved significant breakthroughs in its development of the latest prototype of the LifeAir G1 portable ventilator.



After several trial configurations, Ligand’s engineering team has designed an airway circuitry that delivers maximal tidal volumes even with maximum lung resistance. Putting it in layman’s terms, Dr. Olakulehin stated, “That's technical jargon for ‘the device works!’. We have tested the new airway design on a calibrated test lung, and it is working well.”



As shown in the illustrations below, the system was able to deliver a consistent tidal volume even with changes to the tubing length and system volume



Ligand’s next steps will be to build a 3D printed mock-up of the bag compression mechanism and produce extensive data from the working airway circuitry. A final build of the prototype is expected for late October and an FDA submission should be completed by December 2021. “While supply chain issues remain a challenge, we are cautiously optimistic that we can recoup some of the time delay and perhaps submit ahead of the current target date.”, Dr. Olakulehin concluded.



Forwardly’s Medical Board of Advisors member, Dr. Michael Soffer stated, “The results from the redesigned airway circuitry are very encouraging and I believe that the engineers can finally see the light at the end of the tunnel. I am looking forward to soon flying to Mississauga and watching the prototype function. The medical world has had an urgent need for a device like this even before COVID became relevant.” Dr. Soffer participates in weekly reviews of the project’s development and progress.



About Ligand Innovation Global, Inc.



Ligand IG continues development of the LifeAir G1 Emergency Portable Ventilator to address the expense of conventional ventilator systems which require the intubation and sedation of the patient. Ligand IG expects these units to become readily available, at a greatly reduced cost, to hospitals, nursing homes, and other sites where emergency, life-saving equipment, such as defibrillators are a necessity. Additional information regarding Ligand IG can be found at www.LigandGlobal.com.